ŌURA, creator of its namesake smart ring, has confidentially filed paperwork with the US Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO) of its common stock.
The number of shares to be offered and the price range for the proposed offering have not yet been determined, the company stated. Meanwhile, the specific timing for the IPO was not specified, with ŌURA stating only that it will take place after the SEC “completes its review process, subject to market and other conditions.”
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
While Oura Ring is classified as a consumer wellness product for tracking health metrics, its application has intersected with the medical device industry through various partnerships, notably in the diabetes space.
Dexcom invested $75m in ŌURA in November 2024, forging a partnership centred on launching integrations to facilitate data flow between Dexcom’s continuous glucose monitoring (CGM) products, including its glucose biosensors and apps, with ŌURA products. By integrating Dexcom’s CGM data with Oura ring’s wellness metrics such as sleep, stress, and cardiovascular data, the combined data is positioned to give users insights into aspects such as how poor sleep affects glucose variability and what meals cause glucose spikes.
Other companies that have partnered with ŌURA include Mira. The femtech company announced a collaboration with the company in February 2026, allowing Oura smart ring users to access lab-grade hormone testing data.
On 20 May, ŌURA announced that it was on course to surpass five million paid members this quarter, representing a ‘4x’ uptick over the past two years. The IPO plans follow a $900m Series E financing round completed by the company in October 2025. The latest financing put ŌURA at an approximate valuation of $11bn.
At the time of the Series E round, the company revealed that it had achieved more than $500m in 2024 revenue, doubling its growth from the prior year, and was on course to double revenue again in 2025, surpassing $1bn in annual sales. As of May 2026, the company has not disclosed its 2025 earnings in full.
